Westpac Banking Corp grew its position in shares of Eli Lilly and Co (NYSE:LLY) by 10.9% during the fourth quarter, HoldingsChannel reports. The firm owned 93,869 shares of the company’s stock after acquiring an additional 9,250 shares during the quarter. Westpac Banking Corp’s holdings in Eli Lilly and were worth $7,928,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and in the second quarter valued at $129,000. Willingdon Wealth Management acquired a new stake in shares of Eli Lilly and in the third quarter valued at $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of Eli Lilly and in the third quarter valued at $142,000. Institutional investors own 76.35% of the company’s stock.

LLY has been the topic of several analyst reports. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Thursday, October 26th. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a research note on Wednesday, November 1st. Morgan Stanley increased their price objective on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average price target of $92.75.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock worth $22,041,236 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

Eli Lilly and Co (NYSE:LLY) opened at $85.49 on Friday. The company has a market capitalization of $94,495.98, a price-to-earnings ratio of 40.52, a P/E/G ratio of 1.67 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. equities analysts expect that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.63%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is 98.58%.

COPYRIGHT VIOLATION NOTICE: This report was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://theolympiareport.com/2018/01/20/westpac-banking-corp-grows-holdings-in-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.